The treatment of relapsed/refractory multiple myeloma (MM) has evolved to include several
new options. These include new combinations with second generation proteasome …

Immunomodulatory imide drugs (IMiDs), proteasome inhibitors (PIs) and anti‐CD38
monoclonal antibodies (MoAbs) are the pillars of modern multiple myeloma (MM) therapy …

Therapy for multiple myeloma (MM), a hematologic neoplasm of plasma cells, has
undergone remarkable changes over the past 25 years. Small molecules (molecular weight …

Due to evolving treatment standards for newly diagnosed multiple myeloma, many patients
will be triple-class exposed after initial relapses and have poor survival. Novel therapies and …

Background Selinexor 80 mg combined with low-dose dexamethasone (Sd) demonstrated
significant clinical benefit in patients with relapsed/refractory multiple myeloma (RRMM) who …

Pomalidomide is a potent immunomodulatory agent that is currently a standard of care
backbone for the treatment of multiple myeloma (MM) patients in the relapsed/refractory …

The recent history of multiple myeloma has been marked by tremendous advances in the
treatments available, which have ultimately improved the patients' survival. Immune-based …

Simple Summary Immunotherapy-based treatments have brought many new options in the
treatment of multiple myeloma; still, the disease will inevitably relapse as it remains …

Nuclear export proteins such as exportin-1 (XPO1) transport tumor-suppressor proteins and
other growth-regulatory proteins from the nucleus to the cytoplasm. Overexpression of XPO1 …

Selinexor is a novel and potentially synergistic therapy for lymphoid malignancies, although
requires refined supportive measures and strategies to improve its efficacy. Likely, for …